Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in ... - BioSpace
Ventyx Biosciences initiates Phase 2a trial of VTX3232, an oral NLRP3 inhibitor, in early Parkinson’s disease patients, aiming to assess safety, tolerability, and biomarkers. Topline results expected in 2025.
Reference News
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in ... - BioSpace
Ventyx Biosciences initiates Phase 2a trial of VTX3232, an oral NLRP3 inhibitor, in early Parkinson’s disease patients, aiming to assess safety, tolerability, and biomarkers. Topline results expected in 2025.